Wang Guangqiang, Chu Hongxia, Zhao Na
Department of Cardiology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, 264000 Yantai, Shandong, China.
Department of Rheumatology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, 264000 Yantai, Shandong, China.
Rev Cardiovasc Med. 2023 Jun 12;24(6):170. doi: 10.31083/j.rcm2406170. eCollection 2023 Jun.
Long QT syndrome (LQTS) is an uncommon disorder that is characterized by QT prolongation and torsade de pointes leading to sudden cardiac death. It is mainly triggered by adrenergic activation. Since LQTS is rare, it is often underdiagnosed. The updated 2022 European Society of Cardiology (ESC) guidelines aim to define the diagnosis of LQTS and spread its management. However, some unknowns and uncertainties still exist regarding the treatment of LQTS. This commentary is geared to the expansion of clinical applications of drug therapies for different subtypes of LQTS based on the 2022 ESC guidelines.
长QT综合征（LQTS）是一种罕见的疾病，其特征是QT间期延长和尖端扭转型室速，可导致心源性猝死。它主要由肾上腺素能激活引发。由于LQTS较为罕见，常常诊断不足。2022年欧洲心脏病学会（ESC）更新的指南旨在明确LQTS的诊断并推广其管理方法。然而，关于LQTS的治疗仍存在一些未知和不确定因素。本述评旨在根据2022年ESC指南扩大针对不同亚型LQTS的药物治疗的临床应用。
